IL301663B2 - History of 2-(3-pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl)-acetamide as inhibitors of transforming growth factor receptor I/ALK5 in cells - Google Patents

History of 2-(3-pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl)-acetamide as inhibitors of transforming growth factor receptor I/ALK5 in cells

Info

Publication number
IL301663B2
IL301663B2 IL301663A IL30166323A IL301663B2 IL 301663 B2 IL301663 B2 IL 301663B2 IL 301663 A IL301663 A IL 301663A IL 30166323 A IL30166323 A IL 30166323A IL 301663 B2 IL301663 B2 IL 301663B2
Authority
IL
Israel
Prior art keywords
group
pyrazol
quinolin
methylpyridin
acetamido
Prior art date
Application number
IL301663A
Other languages
English (en)
Hebrew (he)
Other versions
IL301663A (en
IL301663B1 (en
Original Assignee
Agomab Spain S L U
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agomab Spain S L U filed Critical Agomab Spain S L U
Publication of IL301663A publication Critical patent/IL301663A/en
Publication of IL301663B1 publication Critical patent/IL301663B1/en
Publication of IL301663B2 publication Critical patent/IL301663B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL301663A 2020-09-30 2021-09-29 History of 2-(3-pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl)-acetamide as inhibitors of transforming growth factor receptor I/ALK5 in cells IL301663B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20382861.1A EP3978487A1 (en) 2020-09-30 2020-09-30 2-(3-pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl)-acetamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5
PCT/EP2021/076730 WO2022069509A1 (en) 2020-09-30 2021-09-29 2-(3-pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl)-acetamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5

Publications (3)

Publication Number Publication Date
IL301663A IL301663A (en) 2023-05-01
IL301663B1 IL301663B1 (en) 2026-01-01
IL301663B2 true IL301663B2 (en) 2026-05-01

Family

ID=72744716

Family Applications (1)

Application Number Title Priority Date Filing Date
IL301663A IL301663B2 (en) 2020-09-30 2021-09-29 History of 2-(3-pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl)-acetamide as inhibitors of transforming growth factor receptor I/ALK5 in cells

Country Status (20)

Country Link
US (1) US12577230B2 (cg-RX-API-DMAC7.html)
EP (3) EP3978487A1 (cg-RX-API-DMAC7.html)
JP (1) JP7752684B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230079027A (cg-RX-API-DMAC7.html)
CN (1) CN116323601B (cg-RX-API-DMAC7.html)
AR (1) AR123543A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021353965A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023004612A2 (cg-RX-API-DMAC7.html)
CA (1) CA3196108A1 (cg-RX-API-DMAC7.html)
DK (1) DK4222149T3 (cg-RX-API-DMAC7.html)
ES (1) ES3029607T3 (cg-RX-API-DMAC7.html)
FI (1) FI4222149T3 (cg-RX-API-DMAC7.html)
IL (1) IL301663B2 (cg-RX-API-DMAC7.html)
LT (1) LT4222149T (cg-RX-API-DMAC7.html)
MX (1) MX2023002900A (cg-RX-API-DMAC7.html)
PH (1) PH12023550777A1 (cg-RX-API-DMAC7.html)
PT (1) PT4222149T (cg-RX-API-DMAC7.html)
RS (1) RS68301B1 (cg-RX-API-DMAC7.html)
WO (1) WO2022069509A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202302393B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022010251A2 (pt) 2019-11-28 2022-09-06 Origo Biopharma S L Derivados de benzilamida como inibidores do receptor i/alk5 do fator de transformação de crescimento beta
WO2026017797A1 (en) 2024-07-17 2026-01-22 Agomab Spain S.L.U. Crystalline forms
WO2026082960A1 (en) 2024-10-18 2026-04-23 Agomab Therapeutics Nv 1,5-naphtyridine and quinoline based inhibitors of alk5
WO2026082968A1 (en) 2024-10-18 2026-04-23 Agomab Therapeutics Nv Novel compounds
CN121554469B (zh) * 2026-01-23 2026-04-17 四川大学华西医院 一种alk5 protac化合物及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ501112A (en) * 1997-05-22 2002-10-25 G Substituted pyrazoles as p38 kinase inhibitors
US6514977B1 (en) * 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
ATE291020T1 (de) * 2001-02-02 2005-04-15 Smithkline Beecham Corp Pyrazolderivate gegen tgf überexprimierung
WO2004026306A2 (en) 2002-09-18 2004-04-01 Pfizer Products Inc. Pyrazole derivatives as transforming growth factor (tgf) inhibitors
WO2004026302A1 (en) 2002-09-19 2004-04-01 Eli Lilly And Company Methods of inhibiting tgf beta with substituted pyrazoles
CL2004000234A1 (es) 2003-02-12 2005-04-15 Biogen Idec Inc Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
JP2009500419A (ja) * 2005-07-05 2009-01-08 アリックス セラピューティクス、インコーポレイテッド 立体異性体のピリジル及びピリドニル化合物並びに消化管障害及び中枢神経系障害の治療方法
CN102056907B (zh) * 2008-04-04 2014-12-31 武田药品工业株式会社 杂环衍生物及其用途
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
WO2011076725A1 (en) 2009-12-21 2011-06-30 Bayer Cropscience Ag Thienylpyri (mi) dinylazole and their use for controlling phytopathogenic fungi
RU2612958C2 (ru) * 2011-07-13 2017-03-14 Ск Кемикалз Ко., Лтд. 2-пиридилзамещенные имидазолы в качестве ингибиторов alk5 и/или alk4
IN2014CN02805A (cg-RX-API-DMAC7.html) 2011-10-14 2015-07-03 Bristol Myers Squibb Co
WO2016172631A2 (en) 2015-04-24 2016-10-27 President And Fellows Of Harvard College Substrate selective inhibitors of insulin-degrading enzyme (ide) and uses thereof
JP2021518855A (ja) 2018-03-02 2021-08-05 ユニヴェルシテ ド ローザンヌ Wntシグナル伝達経路阻害剤としてのピラゾール誘導体
US11945803B2 (en) 2018-08-07 2024-04-02 Tosk, Inc. Modulators of RAS GTPase
CN110433164A (zh) 2019-08-15 2019-11-12 南开大学 TGF-beta受体分子抑制剂在治疗小鼠动物模型中急性髓系白血病的应用
BR112022010251A2 (pt) 2019-11-28 2022-09-06 Origo Biopharma S L Derivados de benzilamida como inibidores do receptor i/alk5 do fator de transformação de crescimento beta

Also Published As

Publication number Publication date
US20230373966A1 (en) 2023-11-23
KR20230079027A (ko) 2023-06-05
FI4222149T3 (fi) 2026-07-16
MX2023002900A (es) 2023-05-25
EP4222149B1 (en) 2026-05-06
AR123543A1 (es) 2022-12-14
ES3029607T3 (es) 2026-06-23
EP4781988A2 (en) 2026-07-29
LT4222149T (lt) 2026-08-10
AU2021353965A1 (en) 2023-04-27
CN116323601A (zh) 2023-06-23
IL301663A (en) 2023-05-01
PH12023550777A1 (en) 2023-11-20
RS68301B1 (en) 2026-07-31
ES3029607T1 (en) 2025-06-24
CA3196108A1 (en) 2022-04-07
ZA202302393B (en) 2026-03-25
CN116323601B (zh) 2026-05-12
EP3978487A1 (en) 2022-04-06
WO2022069509A1 (en) 2022-04-07
PT4222149T (pt) 2026-06-03
JP2023544716A (ja) 2023-10-25
BR112023004612A2 (pt) 2023-04-11
AU2021353965A9 (en) 2024-08-01
US12577230B2 (en) 2026-03-17
EP4222149A1 (en) 2023-08-09
JP7752684B2 (ja) 2025-10-10
IL301663B1 (en) 2026-01-01
DK4222149T3 (da) 2026-07-27

Similar Documents

Publication Publication Date Title
IL293388B2 (en) History of Benzylamide as Inhibitors of Transforming Growth Factor Receptor I/ALK5
CA3243183A1 (en) RAS ONCOPROTEIN INHIBITORS
IL282552A (en) Crystalline forms of MNK inhibitors
WO2010151710A3 (en) Substituted heterocyclic compounds as kinases inhibitors and method of use thereof
SMT201500090B (it) Inibitori di chinasi di regolazione dei segnali apoptotici
MX394540B (es) Polimorfos y formas solidas de la (s)-2-((2-((s)-4-(difluorometil)-2-oxooxazolidin-3-il)-5,6-dihidrobenzo[f]imidazo[1,2-d] [1,4]oxazepin-9-il)amino)propanamida, y metodos de produccion.
WO2010144499A3 (en) Urea derivatives as kinase inhibitors
PH12020500093A1 (en) Intermediates useful for the synthesis of a selective inhibitor against protein kinase and processes for preparing the same
IL309447A (en) Pharmaceutical preparations of epidermal growth factor receptor inhibitor
IL313548A (en) MET kinase inhibitors
HUE072969T2 (hu) Eljárás anilin és egy anilin-származék elõállítására
IL304329A (en) Use of a melanocortin-4 receptor agonist
IL309469A (en) Salt and crystal forms of epidermal growth factor receptor inhibitor
IL310025A (en) Heterocyclic compounds as MAP4K1 inhibitors
AU2022297794A1 (en) Naltrexone for boosting the therapeutic utility of 5-ht receptor agonists
HK40097824A (en) 2-(3-pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl)-acetamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5
EP3996707A4 (en) CRYSTALLINE FORMS OF PLASMACALLICREIN INHIBITORS
EP3490554A4 (en) USES OF DOPAMINE BETA HYDROXYLASE (DBH) INHIBITORS AND SEROTONIN (5-HT) RECEPTOR ANTAGONISTS FOR CANCER TREATMENT
PT4225739T (pt) Preparação de derivados de benzimidazolona como novos inibidores da diacilglicerol o-aciltransferase 2
BR112023018649A2 (pt) Forma cristalina e método para preparar uma forma cristalina
HK40082084A (en) Benzylamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5
PT3939977T (pt) Cristal de composto de amida heterocíclica e método de produção do mesmo
IL304836A (en) Polymorph of leterpyridine dihydrochloride
IL317760A (en) History of benzocarbazoles as DRP1 inhibitors
MA53914A (fr) Polymorphes cristallins d'inhibiteurs de la tyrosine kinase de bruton